drugset / Trial / NCT00197197

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197197

Phase 3 Terminated 18 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5/X4-tropic virus

Timeline

Start
2005-07
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject APLAVIROC Small molecule 400 mg